Xilio Therapeutics, Inc. - Common Stock (XLO)
Frequently Asked Questions About Xilio Therapeutics, Inc. - Common Stock (XLO)
How can interested parties learn more about Xilio Therapeutics?
Interested parties can learn more about Xilio Therapeutics by visiting the company's official website, which provides information about its ongoing research, clinical trials, news releases, investor relations, and educational resources about cancer and immunotherapy.
How does Xilio communicate with investors?
Xilio Therapeutics maintains open communication with its investors through regular press releases, quarterly earnings calls, investor presentations, and participation in industry conferences. The company also provides updates on its clinical trials and business developments to keep stakeholders informed.
How does Xilio ensure compliance with regulatory requirements?
Xilio Therapeutics is committed to maintaining compliance with regulatory requirements set forth by the U.S. Food and Drug Administration (FDA) and other governing bodies. The company adheres to rigorous protocols during clinical trials, submits necessary documentation, and complies with Good Manufacturing Practices (GMP) to ensure the safety and efficacy of its therapies.
Is Xilio Therapeutics publicly traded?
Yes, Xilio Therapeutics, Inc. is publicly traded on the Nasdaq stock exchange under the ticker symbol XLO. The company went public to raise capital for the further development of its clinical pipeline and to support its ongoing research initiatives.
What are the clinical trial phases for Xilio’s therapies?
Xilio Therapeutics' clinical trials typically progress through the three standard phases: Phase 1 trials focus on assessing safety and dosage, Phase 2 trials evaluate the effectiveness and further assess safety in a larger patient population, and Phase 3 trials are conducted to confirm efficacy and monitor side effects in an even larger group of participants.
What does Xilio Therapeutics, Inc. do?
Xilio Therapeutics, Inc. is a biotechnology company focused on developing innovative cancer therapies. The company specializes in creating an off-the-shelf, selective immune-oncology treatment designed to enhance patient outcomes while minimizing side effects. Xilio is committed to harnessing the power of the immune system to recognize and eliminate tumor cells, ultimately contributing to more effective cancer treatment options.
What is the importance of the immune-oncology approach?
The immune-oncology approach is crucial because it leverages the body's own immune system to identify and attack cancer cells. Unlike traditional therapies, which may harm healthy cells, immune-oncology treatments aim to enhance the immune response specifically against tumors, potentially leading to more effective and sustainable outcomes for cancer patients.
What is the vision of Xilio Therapeutics?
The vision of Xilio Therapeutics is to revolutionize cancer treatment by developing therapies that can selectively enhance the immune system's ability to fight cancer. The company aims to provide patients with more effective, less toxic treatment options, ultimately improving the quality of life for those diagnosed with cancer.
What is Xilio's approach to drug development?
Xilio's approach to drug development emphasizes scientific rigor, precision medicine, and a patient-centric focus. The company leverages advanced technologies to design and optimize its therapies while conducting thorough preclinical and clinical studies to ensure safety and efficacy before bringing products to market.
What is Xilio's lead product candidate?
Xilio's lead product candidate is XTX-101, an investigational therapy aimed at harnessing the body's immune system to better target and destroy cancer cells. XTX-101 has shown promise in preclinical studies and is undergoing clinical trials to evaluate its safety and efficacy in cancer patients.
What is Xilio's strategy for future growth?
Xilio's strategy for future growth involves advancing its clinical pipeline, expanding its product offerings, and exploring potential partnerships and collaborations that align with its mission. The company aims to invest in research and development to drive innovation in cancer therapies and facilitate sustainable growth.
What milestones has Xilio achieved since its founding?
Since its founding in 2018, Xilio Therapeutics has achieved significant milestones, including the advancement of its lead candidate, XTX-101, into clinical trials, successful funding rounds to support its research, and the establishment of key partnerships to expand its scientific capabilities.
What partnerships does Xilio Therapeutics have?
Xilio Therapeutics has established collaborations with various academic institutions and industry partners to advance its research and development initiatives. These partnerships enable the company to leverage shared expertise and resources to expedite the development of its innovative therapies.
What sets Xilio apart from other biotechnology companies?
Xilio Therapeutics distinguishes itself from other biotechnology companies through its unique approach to selective immune-oncology therapies, focusing on off-the-shelf products designed for widespread use. This approach, combined with advanced scientific principles and a strong pipeline, positions Xilio to make a significant impact in the oncology space.
What types of cancer is Xilio targeting?
Xilio Therapeutics is primarily targeting solid tumors, with a focus on cancers such as melanoma, ovarian cancer, and head and neck squamous cell carcinoma. The company aims to develop therapies that can effectively treat these challenging cancers by enhancing immune responses.
When was Xilio Therapeutics, Inc. founded?
Xilio Therapeutics, Inc. was founded in 2018. Since its inception, the company has focused on leveraging advanced scientific research and technological innovations to develop therapies with the potential to transform cancer treatment.
Where is Xilio Therapeutics, Inc. headquartered?
Xilio Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. This location places the company within one of the leading biotech hubs in the United States, which is home to numerous biopharmaceutical companies, cutting-edge research institutions, and a highly skilled workforce.
Who are the founders of Xilio Therapeutics?
Xilio Therapeutics was co-founded by a team of experienced scientists and industry professionals, including co-founders Dr. M. J. (Jay) Tye and Dr. David A. M. Piccirillo. Their diverse backgrounds in immunology, oncology, and drug development bring valuable expertise to the company's mission.
Who is part of Xilio's management team?
Xilio's management team consists of seasoned professionals with extensive experience in biotechnology, drug development, and corporate leadership. Key members include CEO Dr. R. Scott Greer and other executives with strong backgrounds in strategy, research, and operational management within the biotech sector.
What is the current price of Xilio Therapeutics, Inc. - Common Stock?
The current price of Xilio Therapeutics, Inc. - Common Stock is 7.860
When was Xilio Therapeutics, Inc. - Common Stock last traded?
The last trade of Xilio Therapeutics, Inc. - Common Stock was at 4:00 pm EDT on March 20th, 2026
What is the market capitalization of Xilio Therapeutics, Inc. - Common Stock?
The market capitalization of Xilio Therapeutics, Inc. - Common Stock is 407.37M
How many shares of Xilio Therapeutics, Inc. - Common Stock are outstanding?
Xilio Therapeutics, Inc. - Common Stock has 51.83M shares outstanding.